Table 1. FOXP3 expression according to the clinicopathological parameters of our BRCA patients.
| Characteristic | N=123 | Nuclear FOXP3 expression, n (%) | P | |
|---|---|---|---|---|
| Low (n=64) | High (n=59) | |||
| Age, years | 0.484 | |||
| <50 | 68 | 35 (51.5) | 33 (48.5) | |
| ≥50 | 55 | 29 (52.7) | 26 (47.3) | |
| Tumor size, cm | 0.902 | |||
| ≤2.0 | 66 | 34 (51.5) | 32 (48.5) | |
| >2.0 | 57 | 30 (52.6) | 27 (47.4) | |
| Lymph nodes | 0.308 | |||
| Negative | 65 | 31 (47.7) | 34 (52.3) | |
| Positive | 58 | 33 (56.9) | 25 (43.1) | |
| TNM stage | 0.106 | |||
| I | 37 | 14 (37.8) | 23 (62.2) | |
| II | 67 | 38 (56.7) | 29 (43.3) | |
| III | 19 | 12 (63.2) | 7 (36.8) | |
| Histologic grade | 0.766 | |||
| 1 | 26 | 13 (50.0) | 13 (50.0) | |
| 2 | 75 | 38 (50.7) | 37 (49.3) | |
| 3 | 22 | 13 (59.1) | 9 (40.9) | |
| Vessel tumor embolus | 0.024 | |||
| Negative | 86 | 39 (45.3) | 47 (54.7) | |
| Positive | 37 | 25 (67.6) | 12 (32.4) | |
| Ki67 | 0.041 | |||
| Low (≤30%) | 39 | 15 (38.5) | 24 (61.5) | |
| High (>30%) | 84 | 49 (58.3) | 35 (41.7) | |
| ER/PR | 0.092 | |||
| Negative | 57 | 25 (43.9) | 32 (56.1) | |
| Positive | 66 | 39 (59.1) | 27 (40.9) | |
| HER2 | 0.596 | |||
| Negative | 78 | 42 (53.8) | 36 (46.2) | |
| Positive | 45 | 22 (48.9) | 23 (51.1) | |
| Subtype | 0.207 | |||
| Luminal | 66 | 39 (59.1) | 27 (40.9) | |
| HER2 | 32 | 13 (40.6) | 19 (59.4) | |
| TNBC | 25 | 12 (48.0) | 13 (52.0) | |
BRCA, breast carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.